| Followers | 324 |
| Posts | 20195 |
| Boards Moderated | 5 |
| Alias Born | 12/15/2012 |
Thursday, September 11, 2014 6:55:40 PM
$LXRP Great news 07/14/14...:-}
http://finance.yahoo.com/q;_ylt=An38d2_P06EQTydJ5vMQsyUnv7gF?uhb=uhb2&fr=&type=2button&s=lxrp
Jul 14, 2014 (Newsfile Corp via COMTEX) -- Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") is pleased to announce that the production of Medical Marihuana in compliance with Health Canada MMPR regulations has received final Municipal zoning approval for the Lexaria/Enertopia joint venture. Previously announced only as being located in the Greater Toronto Area, now that Municipal approval has been obtained Lexaria is happy to announce the facility location as Burlington, Ontario.
http://finance.yahoo.com/q;_ylt=An38d2_P06EQTydJ5vMQsyUnv7gF?uhb=uhb2&fr=&type=2button&s=lxrp
Jul 14, 2014 (Newsfile Corp via COMTEX) -- Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") is pleased to announce that the production of Medical Marihuana in compliance with Health Canada MMPR regulations has received final Municipal zoning approval for the Lexaria/Enertopia joint venture. Previously announced only as being located in the Greater Toronto Area, now that Municipal approval has been obtained Lexaria is happy to announce the facility location as Burlington, Ontario.
Recent LEXX News
- Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property • ACCESS Newswire • 04/15/2026 01:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/13/2026 05:07:36 PM
- Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval • ACCESS Newswire • 04/07/2026 01:10:00 PM
- Lexaria to Begin New Human Clinical Study in GLP-1 • ACCESS Newswire • 04/01/2026 01:20:00 PM
- Lexaria's Robust Patent Portfolio Continues to Grow • ACCESS Newswire • 03/26/2026 01:20:00 PM
- Lexaria's Oral GLP-1 Drug Strategy Validated by Industry • ACCESS Newswire • 03/24/2026 01:15:00 PM
- Lexaria Announces New R&D Plans for 2026 • ACCESS Newswire • 03/04/2026 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 09:30:40 PM
- Lexaria Announces Positive Final Results From Human Pilot Study #5 • ACCESS Newswire • 02/05/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 06:51:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/28/2026 06:33:53 PM
- Lexaria Awarded Six Additional Patents • ACCESS Newswire • 01/22/2026 02:20:00 PM
- 5 Assets Securing the 2026 Biological Choke Point • GlobeNewswire Inc. • 01/21/2026 02:55:00 PM
- Lexaria Releases Annual Letter from the CEO • ACCESS Newswire • 01/12/2026 02:10:00 PM
- Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/30/2025 02:20:00 PM
- Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/23/2025 02:29:00 PM
- Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/16/2025 09:00:00 PM
- Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/15/2025 01:00:00 PM
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended • ACCESS Newswire • 11/12/2025 02:10:00 PM
- Lexaria Bioscience Corp. Provides Strategic Update • ACCESS Newswire • 10/09/2025 01:20:00 PM
- Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 09/29/2025 08:30:00 PM
- Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 09/26/2025 12:00:00 PM
- Lexaria Bioscience Shares Rise After Reaching GLP-1 Study Milestone • IH Market News • 08/14/2025 02:36:15 PM

